Top 10 Books about Stock Investing to read in 2018. Read more.

INNT - Innovate Biopharmaceuticals, Inc.

INNT - Innovate Biopharmaceuticals, Inc.

#6133()/6630

Fri 20'th Apr 2018

PERIOD 2018-01-22 - 2018-04-20
CHANGE -1.10%
PRICE $20.66
VOLUME
Sell
TREND
Hold

MV LONG
Sell

MV SHORT
Sell

PIVOT
Sell

MACD
Sell

Request Prediction
0.00%
Predict

Innovate Biopharmaceuticals, Inc. Stock Analysis

Technical stock analysis for Fri 20'th Apr 2018

Sell candidate since 2018-04-19 Loss -1.10%

Innovate Biopharmaceuticals, Inc. fell by -1.10% in the last day from $20.89 to $20.66 and has now fallen 4 days in a row. The price has fallen in 6 of the last 10 days and is down by -25.36% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -135 271 shares and in total 167 502 shares bought and sold for approximately $3.46 million.

Shorts 0.53% ( 2018-03-29 )
Cash n/a
Loans n/a
Beta -14.77
ROA -247.05

Trend

Innovate Biopharmaceuticals, Inc. has broken the very wide and strong rising short-term trend down. This signalize a slower rising rate, but may also be an early warning about a possible trend shift. Due to trend being broken there will now be resistance at the bottom line of the trend at $26.34. A reaction back to this level may hold a second chance to get out before further falls.

Click here for today's Top 5 Trending Companies

Signals

There are few to none technical positive signals at the moment. Innovate Biopharmaceuticals, Inc. holds sales signals from both short- and long-term moving averages. On corrections up there will be some resistance from the lines at $25.85 and $23.29. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Tuesday April 17, 2018, which indicates further falls until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 39 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

On the downside, the stock finds support just below today's level from accumulated volume at $18.82 and $17.30. On the upside the stock meets some resistance just above today's level from accumulated volume at $21.34, $25.00 and $25.65.

There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Innovate Biopharmaceuticals, Inc. finds support just below today's level at $18.82. If this is broken, then the next support from accumulated volume will be at $17.30 and $17.00. The stock is about to test the resistance from accumulated volume at $21.34 and this may cause the stock to take a minor break or get into a more sideways move for a few days.

Support: $18.82 Price: $20.66 Resistance: $21.34

Risk

This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $2.26 between high and low, or 11.47%. For the last week, the stock has had a daily average volatility of 15.81%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

Overall risk:

Very Low Low Medium High Very High

Evaluation

The Innovate Biopharmaceuticals, Inc. stock holds several negative signals and despite the positive trend we believe Innovate Biopharmaceuticals, Inc. will perform weak in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. We have upgraded our recommendation for this stock since last evaluation from a Strong Sell Candidate to a Sell Candidate.

Trade INNT CFDs with Plus500

Your capital is at risk.

Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).

Access these features

Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder
Ad-free browsing

Become a PRO Now
Help us IMPROVE our CHARTS HERE.

Last donation

Do you find our website useful too?
Help us improve by making a small donation or
Get PRO features

START FREE 5-DAY TRIAL